Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Ola Attman

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 8, 2014
End-stage renal disease associated with prophylactic lithium treatmentHarald Aiff, Per-Ola Attman, Mattias Aurell, et al.
Journal of Psychopharmacology (Oxford, England)|November 14, 2014
Reply to letter to the editorHarald Aiff, Per-Ola Attman, Hans Bendz, et al.
Kidney International. Supplement|April 16, 2003
Dialysis modalities and dyslipidemiaPer-Ola Attman, Ola Samuelsson, Ann-Cathrine Johansson, et al.
Journal of Psychopharmacology (Oxford, England)|June 14, 2018
Compliance with the safety guidelines for long-term lithium treatment in SwedenMihaela Golic, Harald Aiff, Per-Ola Attman, et al.
Journal of Psychopharmacology (Oxford, England)|December 19, 2013
The impact of modern treatment principles may have eliminated lithium-induced renal failureHarald Aiff, Per-Ola Attman, Mattias Aurell, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 5, 2002
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiencyOla Samuelsson, Per-Ola Attman, Carolyn Knight-Gibson, et al.
Journal of Psychopharmacology (Oxford, England)|March 5, 2015
Effects of 10 to 30 years of lithium treatment on kidney functionHarald Aiff, Per-Ola Attman, Mattias Aurell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 2, 2005
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemiaPer-Ola Attman, Pia Ottosson, Ola Samuelsson, et al.
Journal of Psychopharmacology (Oxford, England)|July 15, 2020
Starting lithium in patients with compromised renal function - is it wise?Mihaela Golic, Harald Aiff, Per-Ola Attman, et al.
Journal of Psychopharmacology (Oxford, England)|September 19, 2022
The low risk for early renal damage during lithium treatment has not changed over timeMihaela Golic, Harald Aiff, Per-Ola Attman, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 8, 2014
End-stage renal disease associated with prophylactic lithium treatmentHarald Aiff, Per-Ola Attman, Mattias Aurell, et al.
Journal of Psychopharmacology (Oxford, England)|November 14, 2014
Reply to letter to the editorHarald Aiff, Per-Ola Attman, Hans Bendz, et al.
Kidney International. Supplement|April 16, 2003
Dialysis modalities and dyslipidemiaPer-Ola Attman, Ola Samuelsson, Ann-Cathrine Johansson, et al.
Journal of Psychopharmacology (Oxford, England)|June 14, 2018
Compliance with the safety guidelines for long-term lithium treatment in SwedenMihaela Golic, Harald Aiff, Per-Ola Attman, et al.
Journal of Psychopharmacology (Oxford, England)|December 19, 2013
The impact of modern treatment principles may have eliminated lithium-induced renal failureHarald Aiff, Per-Ola Attman, Mattias Aurell, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 5, 2002
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiencyOla Samuelsson, Per-Ola Attman, Carolyn Knight-Gibson, et al.
Journal of Psychopharmacology (Oxford, England)|March 5, 2015
Effects of 10 to 30 years of lithium treatment on kidney functionHarald Aiff, Per-Ola Attman, Mattias Aurell, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 2, 2005
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemiaPer-Ola Attman, Pia Ottosson, Ola Samuelsson, et al.
Journal of Psychopharmacology (Oxford, England)|July 15, 2020
Starting lithium in patients with compromised renal function - is it wise?Mihaela Golic, Harald Aiff, Per-Ola Attman, et al.
Journal of Psychopharmacology (Oxford, England)|September 19, 2022
The low risk for early renal damage during lithium treatment has not changed over timeMihaela Golic, Harald Aiff, Per-Ola Attman, et al.
Pageof 3